321 related articles for article (PubMed ID: 28287346)
1. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
Fleetwood K; McCool R; Glanville J; Edwards SC; Gsteiger S; Daigl M; Fisher M
J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S5-S16. PubMed ID: 28287346
[TBL] [Abstract][Full Text] [Related]
2. Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis.
Fisher M; Nathan SD; Hill C; Marshall J; Dejonckheere F; Thuresson PO; Maher TM
J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S17-S24. PubMed ID: 28287347
[TBL] [Abstract][Full Text] [Related]
3. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
[TBL] [Abstract][Full Text] [Related]
4. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.
Rochwerg B; Neupane B; Zhang Y; Garcia CC; Raghu G; Richeldi L; Brozek J; Beyene J; Schünemann H
BMC Med; 2016 Feb; 14():18. PubMed ID: 26843176
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
6. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.
Di Martino E; Provenzani A; Vitulo P; Polidori P
Ann Pharmacother; 2021 Jun; 55(6):723-731. PubMed ID: 33054319
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
9. Comparing new treatments for idiopathic pulmonary fibrosis--a network meta-analysis.
Loveman E; Copley VR; Scott DA; Colquitt JL; Clegg AJ; O'Reilly KM
BMC Pulm Med; 2015 Apr; 15():37. PubMed ID: 25927225
[TBL] [Abstract][Full Text] [Related]
10. Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
Canestaro WJ; Forrester SH; Raghu G; Ho L; Devine BE
Chest; 2016 Mar; 149(3):756-66. PubMed ID: 26836914
[TBL] [Abstract][Full Text] [Related]
11. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Nathan SD; Albera C; Bradford WZ; Costabel U; Glaspole I; Glassberg MK; Kardatzke DR; Daigl M; Kirchgaessler KU; Lancaster LH; Lederer DJ; Pereira CA; Swigris JJ; Valeyre D; Noble PW
Lancet Respir Med; 2017 Jan; 5(1):33-41. PubMed ID: 27876247
[TBL] [Abstract][Full Text] [Related]
12. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study.
Kim JS; Murray S; Yow E; Anstrom KJ; Kim HJ; Flaherty KR; Martinez FJ; Noth I
Chest; 2024 May; 165(5):1163-1173. PubMed ID: 38030064
[TBL] [Abstract][Full Text] [Related]
14. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
[TBL] [Abstract][Full Text] [Related]
15. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
[TBL] [Abstract][Full Text] [Related]
16. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
[TBL] [Abstract][Full Text] [Related]
17. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
18. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
Noor S; Nawaz S; Chaudhuri N
Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials.
Wu X; Li W; Luo Z; Chen Y
BMC Pulm Med; 2024 Jan; 24(1):58. PubMed ID: 38281037
[TBL] [Abstract][Full Text] [Related]
20. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
